Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: A case report and review of the literature

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2509-2513

  Gadducci, Angiolo ^a   Gargini, Antonio ^a   Palla, Elisabetta ^a   Fanucchi, Antonio ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Chemotherapy; Neutropenic enterocolitis; Ovarian cancer; Paclitaxel

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; PACLITAXEL; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL RADIOGRAPHY; ADULT; ADVANCED CANCER; ANAMNESIS; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CANCER RECURRENCE; CASE REPORT; DRUG DOSE REDUCTION; EPITHELIUM TUMOR; ESCHERICHIA COLI; FECES CULTURE; FEMALE; HISTOPATHOLOGY; HUMAN; NEUTROPENIC ENTEROCOLITIS; OVARY CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SALVAGE THERAPY; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; ENTEROCOLITIS, NEUTROPENIC; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 22944468477     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Archibald RB and Nelson JA: Necrotizing enterocolitis in acute leukemia: radiographic findings. Gastrointest Radiol 3: 63-65, 1978.
2. Maeta M, Mizusawa K and Koga S: Induction of diffuse necrotizing enterocolitis by anticancer chemotherapy. Gastroenterol Jpn 22: 370-373, 1987.
3. Stellato TA and Shenk RR: Gastrointestinal emergencies in the oncology patient. Semin Oncol 16: 521-531, 1989.
4. Petruzzelli GJ, Johnson JT and deVries EJ: Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy. Arch Otolaryngol Head Neck Surg 776: 209-211, 1990.
5. de Gara CJ, Gagic N, Arnold A and Seaton T: Toxic megacolon associated with anticancer chemotherapy. Can J Surg 34: 339-341, 1991.
6. Or R, Mehta J, Nagler A and Craciun I: Neutropenic enterocolitis associated with autologous bone marrow transplantation. Bone Marrow Transplant 9: 383-385, 1992.
7. Pouwels MJM, Donnelly JP, Raemaekers JM, Verweij PE and de Pauw BE: Clostridium septicum sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. Ann Hematol 74: 143-147, 1997.
8. Ferrazzi E, Toso S, Zanotti M and Giuliano G: Typhlitis (neutropenic enterocolitis) after a single dose of vinorelbine. Cancer Chemother Pharmacol 47: 277-279, 2001.
9. Hogan WJ, Letendre L, Litzow MR, Tefferi A, Hoagland HC, Pruthi RK and Kaufmann SH: Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc 77: 760-762, 2002.
10. Camera A, Andretta C, Villa MR, Volpicelli M, Picardi M, Rossi M, Rinaldi CR, Della Cioppa P, Ciancia R, Selleri C and Rotoli B: Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Hematol J 4: 346-350, 2003.
11. Geisler JP, Schraith DF, Manahan KJ and Sorosky JI: Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer. Gynecol Oncol 92: 705-707, 2004.
12. Dosik GM, Luna M, Valdivieso M, McCredie KB, Gehan EA, Gil-Extremera B, Smith TL and Bodey GP: Necrotizing colitis in patients with cancer. Am J Med 67: 646-656, 1979.
13. Keidan RD, Fanning J, Gatenby RA and Weese JL: Recurrent typhlitis. A disease resulting from aggresive chemotherapy. Dis Colon Rectum 32: 206-209, 1989.
14. Gomez L, Martino R and Rolston KV: Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis 27: 695-699, 1998.
15. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU and Hortobagyi GN: Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355: 281-283, 2000.
16. Olithselvan A and Gorard DA: Vinorelbine and ischaemic colitis. Clin Oncol (R Coll Radiol) 15: 166-167, 2003.
17. Seewaldt V, Cain JM, Greer BE, Tamimi H and Figge DC: Bowel complications with taxol therapy. J Clin Oncol 11: 1198, 1993.
18. Pestalozzi BC, Sotos GA, Choyke PL, Fisherman JS, Cowan KH and O'Shaughnessy JA: Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer 71: 1797-1800, 1993.
19. Rose PG and Piver MS: Intestinal perforation secondary to paclitaxel. Gynecol Oncol 57: 270-272, 1995.
20. Seewaldt VL, Cain JM, Goff BA, Tamimi H, Greer B and Figge D: A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer. Gynecol Oncol 67: 137-140, 1997.
21. Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K and Rowinsky EK: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14: 783-791, 1996.
22. Cardenal F, Montes A, Llort G, Segui J and Mesia R: Typhlitis associated with docetaxel treatment. J Natl Cancer Inst 88: 1078-1079, 1996.
23. Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thurlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A and Goldhirsch A: Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 10: 539-545, 1999.
24. Resnik E and Lefevre CA: Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer 9: 512-514, 1999.
25. Kouroussis C, Samonis G, Androulakis N, Souglakos J, Voloudaki A, Dimopoulos MA, Kotsakis T, Kakolyris S, Kalbakis K and Georgoulias V: Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. Am J Clin Oncol 23: 309-313, 2000.
26. Kreis W, Petrylak D, Savarese D and Budman D: Colitis and docetaxel-based chemotherapy. Lancet 355: 2164, 2000.
27. Sezer O, Eucker J and Possinger K: Colitis associated with docetaxel-based chemotherapy. Lancet 355: 1823-1824, 2000.
28. Yamazawa K, Kanno H, Seki K, Kuzuta T, Matsui H and Sekiya S: Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy. Acta Obstet Gynecol Scand 80: 768-769, 2001.
29. Daniele B, Rossi GB, Losito S, Gridelli C and de Bellis M: Ischemic colitis associated with paclitaxel. J Clin Gastroenterol 33: 159-160, 2001.
30. Stemmler HJ, Kenngotte S, Diepolder H and Heinemann V: Gastrointestinal toxicity associated with weekly docetaxel treatment. Ann Oncol 13: 978-981, 2002.
31. Tashiro M, Yoshikawa I, Kume K and Otsuki M: Ischemic colitis associated with paclitaxel and carboplatin chemotherapy. Am J Gastroenterol 98: 231-232, 2003.
32. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU and Hortobagyi GN: Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101: 1508-1513, 2004.
33. Hruban RH, Yardley JH, Donehower RC and Boitnott JK: Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63: 1944-1950, 1989.
34. Urbach DR and Rotstein OD: Typhlitis. Can J Surg 42: 415-419, 1999.
35. Rolsten KVI and Bodey GP: Infections in patients with cancer. In: Cancer Medicine. (Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF and Frei III E, eds.), 5th Ed. New York: BC.Decker, Inc. pp. 2407-2432, 2000.
36. Emoto M, Kawarabayashi T, Hachisuga T, Eguchi F and Shirakawa K: Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 61: 369-372, 1996.
37. Husain A, Aptaker L, Spriggs DR and Barakat RR: Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 71: 104-107, 1998.
38. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
39. Conte PF, Cianci C and Gadducci A: Update in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol 32: 49-58, 1999.
40. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708, 2000.
41. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B and van Houwelingen HC: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092, 2000.
42. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R: Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200, 2003.
43. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and Pfisterer J: Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1309-1329, 2003.
44. Mano MS, Awada A, Minisini A, Atalay G, Lago LD, Cardoso F and Piccart M: Remaining controversies in the upfront management of advanced ovarian cancer. Int J Gynecol Cancer 14: 707-720, 2004.
45. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N and Hayn R: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 77: 2405-2410, 1993.
46. Rose PG, Fusco N, Fluellen L and Rodriguez M: Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 76: 1494-1497, 1998.
47. Gadducci A, Conte P, Cianci C, Negri S and Genazzani AR: Treatment options in patients with recurrent ovarian cancer. Anticancer Res 27: 3557-3564, 2001.
48. Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E and Spriggs DR: Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 20: 1238-1247, 2002.
49. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A and Trope C: ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106, 2003.